Login / Signup

Efficacy and safety of recombinant human lymphotoxin-α derivative with cisplatin and fluorouracil in patients with metastatic esophageal squamous cell carcinoma: A randomized, multicenter, open-label, controlled, phase 2b trial.

Feng-Hua WangYun WangGuo-Ping SunJian-Hua ChenYing-Cheng LinWei LiuRong-Sheng ZhengJia ChenHe-Long ZhangHai-Tao LanJun QiYang-Qing LiuYan-Ming DengHeng ZhaoJian-Ping XiongQing XuWen-Qi JiangYu-Hong Li
Published in: Cancer (2017)
rhLTα-Da combined with the PF regimen failed to improve PFS and ORR in patients with mESCC, except in a small subset that had low serum TNFR II concentrations. Cancer 2017;123:3986-94. © 2017 American Cancer Society.
Keyphrases
  • papillary thyroid
  • open label
  • recombinant human
  • clinical trial
  • squamous cell
  • phase iii
  • phase ii
  • study protocol
  • lymph node metastasis
  • cross sectional
  • childhood cancer
  • radiation therapy
  • phase ii study